

Broncho-vaxom® Adults / Children

COMPOSITION

a) Active principle:

Lyophilized bacterial lysates of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis.

b) Other ingredients:

- Capsules: antiox. propyl gallate (E 310), glutamate, indigotine (E132), excipients for capsule.
- Sachets: antiox. propyl gallate (E 310), glutamate, excipients for sachet.

PHARMACEUTICAL FORMS AND QUANTITIES OF ACTIVE PRINCIPLE

Capsules for adults : 40 mg of standardized lyophilizate corresponding to 7 mg of lyophilizate bacterial lysates.

Capsules and Sachets for children : 20 mg of standardized lyophilizate corresponding to 3.5 mg of lyophilizate bacterial lysates.

INDICATIONS / POSSIBILITIES OF USE

Immunotherapy

Prevention of recurrent infections of the airways and acute infectious exacerbations of chronic bronchitis. Comedication in the treatment of acute airway infections.

POSOLOGY / METHOD OF ADMINISTRATION

Adults:

Preventive treatment and/ or consolidation therapy: one capsule daily on an empty stomach during 10 consecutive days per month for 3 months.

Treatment of acute episodes: one capsule daily on an empty stomach until disappearance of the symptoms (but for at least 10 days). In cases in which antibiotics are needed, the administration of Broncho-Vaxom® should be associated preferably from the start of therapy.

Pediatrics (Children aged from 6 months to 12 years):

Same treatment schedule as for adults, one capsule Broncho-Vaxom® Children or one sachet Broncho-Vaxom® containing half the dose of Broncho-Vaxom® Adults.

Note: If a child has difficulty in swallowing the capsules, it can be opened and its content may be poured into a drink (water, fruit juice, milk, etc., ...). In this case, the sachet form, better adapted to pediatric use, should be preferred. The content of the sachet must be poured into a drink (water, fruit juice, milk, etc., ...).

Once the content of the sachet is dissolved, the preparation must be swallowed immediately. Do not conserve the mixture.

CONTRA-INDICATIONS

Hypersensitivity towards the active principle or one of the excipients of Broncho-Vaxom® indicated in the composition.

SPECIAL WARNINGS AND PRECAUTIONS

On the basis of present knowledge, the administration of Broncho-Vaxom® to children aged less than 6 months is not recommended, because of the immaturity of their immune system.

INTERACTIONS

No drug interaction is known up to now.

PREGNANCY AND BREAST FEEDING

No clinical data on the use of the product in pregnant women is available. Studies in animals did not reveal direct or indirect toxic effect on the pregnancy, embryonal/ foetal or post-natal development. As regards breast feeding, no specific studies have been performed and no

data have been reported up to now. The product should be administered cautiously during pregnancy and breast feeding.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Broncho-Vaxom® does not have any influence on ability to drive and use machines.

UNDESIRABLE EFFECTS

The overall incidence of undesirable effects in clinical trials lies between 3 - 4%. Gastrointestinal troubles (nausea, abdominal pain, vomiting), skin reactions (rash, urticaria), and respiratory disorders (coughing, dyspnea, asthma), as well as generalized problems (fever, fatigue, allergic reactions) are the most frequent complaints reported. In case of lasting gastrointestinal disorders, treatment should be interrupted. In case of long-lasting skin reactions and respiratory problems, the treatment should be interrupted as these may constitute allergic reactions.

OVERDOSE

No case of overdose known up to now. Due to the nature of Broncho-Vaxom® and the results of toxicity tests performed in animals, an overdosage seems impossible to reach.

PROPERTIES / EFFECTS

ATC code: R07AX - Other respiratory system products.

In humans, an increase in the rate of circulating T-lymphocytes, in salivary IgA, in the non-specific response to polyclonal mitogens and in the mixed lymphocyte reaction have been observed.

PHARMACOKINETICS

No experimental model available up to now.

PRECLINICAL DATA

In animals, an increased resistance towards experimental infections, a stimulation of macrophages and B- lymphocytes as well as an increase in immunoglobulins secreted by the respiratory mucosal cells have been reported.

Extensive toxicity studies have not revealed any toxic effect.

PARTICULAR REMARKS

Incompatibilities

No known up to now

Influence on methods of diagnosis

Irrelevant

Special precautions for storage

The medication should be stored protected from heat (15-25°C).

The medication should not be used after the expiration date stated on the package together with the mention "EXP".

Instructions for handling

No special instructions.

PRESENTATIONS

Boxes containing 1 blister of 10 capsules (blue capsules for adults and blue/white capsules for children).

Boxes of 10 sachets.

OM
P H A R M A

MINAPHARM
Under Licence of
OM PHARMA
Switzerland


MINAPHARM